Published in final edited form as:

Semin Oncol. 2011 October ; 38(5): 667–672. doi:10.1053/j.seminoncol.2011.04.006.

Immunological aspects of hypoplastic myelodysplastic syndrome

Rodrigo T. Calado, MD/PhD

Staff Scientist, Hematology Branch, National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, MD 20892

Abstract

The pathophysiology of myelodysplastic syndromes (MDS) is multiple, complex, and poorly understood. In some cases of MDS, especially in which the bone marrow is hypocellular, there is increasing experimental and clinical indication that an immune-mediated damage to hematopoietic precursors and changes in the hematopoiesis-supporting microenvironment contribute to disease development. Increased serum levels of type-1 cytokines tumor necrosis factor- α and interferon- γ , and oligoclonal expansion of cytotoxic T cells are observed in human MDS. In some cases, the immunological attack to the marrow appears to be triggered by MDS-specific antigens, damaging the microenvironment and inducing cell apoptosis especially of normal progenitors. In murine models, dysregulation of osteoprogenitors leads to disrupted hematopoiesis of healthy hematopoietic progenitor and stem cells, eventually resulting in MDS and leukemia. In hypocellular MDS, marrow failure appears to be not only the result of ineffective erythropoiesis of abnormal clones, but also due to inhibition of normal progenitors. Immunosuppressive therapy with cyclosporine, anti-thymocyte globulin, or alemtuzumab may alleviate cytopenias and in some instances induce cytogenetic remission. However, not all patients respond to immunosuppression, and the identification of relevant biomarkers for an immune mechanism is necessary to identify those patients who may benefit from this treatment modality.

INTRODUCTION

Myelodysplastic syndromes (MDS) are a very heterogeneous group that represents a spectrum of diseases characterized by ineffective erythropoiesis and marrow failure limited by acute and chronic leukemias and myeloproliferative disorders in one end of the spectrum, in which hypercellular marrow is typical, to aplastic anemia at the other end. Since thresholds are arbitrary and do not necessarily reflect disease biology, it is often difficult to establish the differences between hypoplastic MDS (hMDS) and aplastic anemia, or refractory anemia with excess blasts-2 (RAEB-2) MDS and acute leukemia. A few MDS cases have distinct etiology and pathophysiology, such as 5q⁻ syndrome, in which a specific chromosomal lesion leads to abnormal gene expression (*RPS14*) and disease phenotype (1); it is likely due to the distinct genetic basis that 5q⁻ syndrome uniquely respond to specific therapy (2). This etiologic feature is not present in most types of MDS, which are categorized based on secondary events in disease pathophysiology due to our limitations to understand their etiology and pathophysiology.

Correspondence: Rodrigo T. Calado, MD/PhD, 10 Center Drive, Bldg. 10/CRC, Rm 3E5140, Bethesda, MD 20892, Tel: (301) 496.5093, Fax: (301) 496.8396, calador@nhlbi.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Hypoplastic MDS refers to a morphologic feature in which the marrow cellularity is low for age (<30% cellularity if <60 years or <20% cellularity if age >60 years), representing approximately 10 to 15% of all MDS cases, but which does not necessarily take into account disease mechanism (3). However, hMDS does not represent a defined MDS category according to the WHO classification, but rather denotes the morphologic status of other MDS categories. Nevertheless, patients with hMDS tend to be younger, have more profound neutropenia and thrombocytopenia, lower percentage of blasts, and less likely to display abnormal karyotype in comparison to patients with normocellular or hypercellular MDS (4). The prognostic significance of hMDS is still debatable, according to the WHO classification; patients with hMDS had a more favorable overall survival compared to normo/hypercellular MDS in some studies (5;6), but not in others (7).

HYPOPLASTIC MDS AND APLASTIC ANEMIA

Due to its similarities and often-difficult differential diagnosis (8), hMDS is inferred to share pathophysiologic mechanisms with acquired aplastic anemia, and more likely to be immune-mediated (9). However, evidence for an immune process is not restricted to this hMDS. The differential diagnosis between aplastic anemia and hMDS is mainly based on the presence of dysgranulopoiesis, dysmegakaryocytopoiesis, increased percentage of blasts, and abnormal karyotype, all favoring the diagnosis of hMDS. In addition, an abnormal antigen expression pattern in marrow CD34⁺ cells (10) indicating an aberrant clone, and elevated hemoglobin F-containing erythroblast production (11) suggest the diagnosis of hMDS. However, findings compatible with an immune process (relative lymphocytosis in the marrow and oligoclonal T-cell expansion, increased cytokine levels) do not contribute to differential diagnosis, as these elements are present in both diseases. The overlap of immunological aspects suggests that hMDS and aplastic anemia share an immune-mediated mechanism.

Paroxysmal nocturnal hemoglobinuria (PNH) clones, which are deficient for glycosyl-phosphatidylinositol (GPI)-anchored proteins, also are observed in up to 20% of MDS cases (12;13). The emergence of a PNH clone derived from mutant hematopoietic stem cells is frequently observed in acquired aplastic anemia and is interpreted as an “escape” from the immune attack directed against hematopoietic progenitors. For reasons poorly understood, GPI-anchored protein-deficient cells appears to be spared by the immune process mediated by T cells in marrow failure and the occurrence of a PNH clone is interpreted as a sign of an immune pathophysiology (14). In MDS, the presence of a detectable PNH clone is more common in low risk cases (refractory anemia and refractory cytopenias with multilineage dysplasia (15). Patients with refractory anemia MDS with a PNH clone, suggesting an immune mechanism, have a distinct feature: the morphologic dysplastic abnormalities are less dramatic, the presence of abnormal karyotype is less common, and progression to acute leukemia is infrequent (13). However, the presence of a PNH clone is not restricted to hMDS.

Aplastic anemia and hMDS also may share genetic defects. Mutations in genes encoding the telomerase complex, responsible for maintaining the length of telomeres, results in excessive telomere shortening in hematopoietic progenitors, are etiologic in dyskeratosis congenita, an inherited bone marrow failure syndrome, and also are found in some cases of apparently acquired aplastic anemia (16). Dyskeratosis congenita has a high probability for progression to MDS and acute leukemia (17), and aplastic anemia patients with telomerase mutations also often evolve to hMDS and acute myeloid leukemia (18). Acquired aplastic anemia patients with shorter telomeres (lowest quartile for telomere length) are those with higher risk to evolve to MDS, especially monosomy 7 (19).

Mutations in *TERC* (encoding the RNA component of telomerase) or *TERT* (encoding the telomerase reverse transcriptase enzyme) also are found in a minority of patients with MDS (20;21). Hypoplastic MDS also may be the primary clinical manifestation of telomerase deficiency, especially in children (22;23).

IMMUNOLOGICAL CHANGES IN hMDS

Similar to acquired aplastic anemia, several abnormalities indicative of an active immune process mediated by a Th1-cell response are observed in MDS, including hMDS.

Abnormal Cytokine Profile

Cytokines are usually abnormally expressed in MDS. Tumor necrosis factor- α (TNF- α) is consistently high in bone marrow samples of patients with MDS, regardless of morphological subtype (24;25). However, TNF- α is most prominent in low-risk MDS (26). Serum levels of TNF- α also are increased in MDS (27). In addition, the TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, also is overexpressed in MDS (28). TRAIL, usually not present in healthy marrows, induces apoptosis by activating agonistic receptors 1 and 2 and decoy receptors 3 and 4 (9). In MDS, TRAIL preferentially targets abnormal clonal cells with aberrant chromosomes, inducing apoptosis (28). The expression of TRAIL agonistic receptors is significantly higher in MDS marrow cells as compared to healthy marrows. In addition, MDS marrow cells display lower levels of FLIP, a cytoplasmic inhibitor of apoptosis, which may explain the higher sensitivity to TRAIL in cytogenetically abnormal clones. In fact, the FLIP long isoform (FLIP_L) is under-expressed in marrow CD34⁺ cells of patients with MDS. Interferon- γ (INF- γ) also is overexpressed by marrow mononuclear cells in MDS (25;27). Both TNF- α and IFN- γ activate the expression of induced nitric oxide synthase (iNOS) by MDS cells, which can potentially mediate the dysregulation of hematopoiesis in MDS (29). In hematopoietic cells, iNOS appears to engage Fas-mediated apoptosis (30) and this may be an additional immune-mediated mechanism contributing to ineffective hematopoiesis in MDS.

Finally, cytokine expression profile also may have prognostic significance. In a recent study, interleukin-4 (IL-4) and C-C motif chemokine 3 (CCL3) serum levels were consistently under-expressed in MDS and independently associated with survival (31).

T-Cell Mediated Attack

In acquired aplastic anemia, there is compelling laboratory evidence that marrow failure is the result of an antigen-driven lymphocyte destruction of the hemopoietic tissue (32;33). In these patients, there is an expansion of cytotoxic T cells expressing defined T-cell-receptor (TCR) V β chain, indicating the oligoclonality of the T-cell repertoire (32). Similar V β -chain usage is observed in MDS; skewed T-cell populations are observed in treatment-naïve MDS patients, which are reduced or disappear after response to immunosuppressive therapy (34–37). Conversely, in patients who fail immunosuppression, the dominant T-cell clone persists after treatment.

Although the antigens triggering the immune response in MDS are not known, some molecules are potential candidates. Trisomy 8 patients often respond to immunosuppression, indicating a strong immunological mechanism underlying marrow failure in this disease (9). Trisomy 8 cells express high levels of WT1, a zinc finger transcription factor implicated in the pathophysiology of Wilms tumor. CD8⁺ T cells of patients with trisomy 8 are able to recognize WT1 peptides and engage INF γ expression in vitro, suggesting that this antigen may contribute to elicit an immune response (9). Whether WT1 antigenicity may be used therapeutically is still unknown.

Further evidence supporting an autoimmune component in MDS is genetic. Several autoimmune diseases are associated with specific HLAs and among marrow failure syndromes, acquired aplastic anemia has been linked to HLA-DR15, a serologic split of HLA-DR2 (33;38). HLA-DR15 antigen also is overrepresented in patients with refractory anemia MDS when compared to healthy controls (39); HLA-DR15 allele frequency also is significantly higher in patients with MDS bearing a PNH clone (13). Taken together, these observations further suggest that some MDS cases are immune-mediated.

MICROENVIRONMENT CHANGES IN MDS

Recent observations have changed the way we understand leukemogenesis and how the marrow microenvironment (niche) may contribute to malignant clonal evolution (40). Conditional deletion of *Dicer1*, an RNase III endonuclease essential for microRNA biogenesis and RNA processing, in murine osteoprogenitors led to various degrees of cytopenias and dysplastic changes in myeloid and megakaryocytic lineages in spite of hematopoietic cells having intact *Dicer1*. Interestingly, transplantation of hematopoietic cells from conditionally knock-out *Dicer1* animals, which showed dysplastic changes but normal *Dicer1* gene, into wild-type mice resulted in recovery of normal hematopoiesis after engraftment; conversely, wild-type marrows transplanted into *Dicer1* knock-out mice showed dysplastic abnormalities after engraftment, both indicating that myelodysplasia was induced by the marrow microenvironment. *Dicer1*-knockout mice also evolved to tissue infiltration with blasts (myeloid sarcomas), splenic infiltration, and circulation monocytoid cells, resembling human acute myelomonocytic or monoblastic leukemia. However, in this mouse model, the marrows did not become hypocellular.

Gene expression analysis indicated consistent down-regulation of the *Sbds* gene. Biallelic mutations in human *SBDS* is etiologic in Shwachman-Diamond syndrome, an inherited bone marrow failure syndrome characterized by aplastic anemia, pancreatic exocrine insufficiency, and proclivity to develop MDS involving the chromosome 7 (41).

CLINICAL RESPONSE TO IMMUNOSUPPRESSION

That some patients with MDS respond to immunosuppressive therapy is compelling evidence for an immune-mediated mechanism. As for most patients with low-risk MDS, mortality is associated with complications from marrow failure and not evolution to acute leukemia, therapies aiming to alleviate cytopenias are warranted. Immunosuppressive regimens are effective to induce hematopoietic response in acquired aplastic anemia, ameliorating peripheral blood cytopenias and recovering marrow cellularity (33). Several investigators around the world have tried immunosuppressive therapy for MDS using different agents: cyclosporine (42), methylprednisolone and cyclosporine (43), anti-thymocyte globulin and/or cyclosporine (7;44–48), or alemtuzumab (9) (Table 1).

In a Czech study 17 patients with MDS were treated with cyclosporine alone (42). Most patients had refractory anemia MDS and the majority were hMDS. The authors observed a significant persistent response with transfusion independence in 14/17 patients; in a minority of patients, cyclosporine was discontinued due to toxic side effects. Conversely, in a small British study (six patients), none of the patients responded to cyclosporine alone (49). Cyclosporine was added to methylprednisolone in a Japanese study of 18 patients with MDS (43); only six patients received cyclosporine and most patients had refractory anemia MDS. One third of patients responded to therapy.

The combination of anti-thymocyte globulin and cyclosporine is known to be more effective than any of the agents alone in acquired aplastic anemia (50). Several trials have investigated this immunosuppressive therapy in MDS (7;45;48). The response rate varied

from 16 to 45 percent, but patients with hMDS did not show a statistically significant better response to immunosuppression than normo/hypercellular MDS (7). In a larger trial at NIH, patients received either anti-thymocyte globulin as single agent (n=74), cyclosporine alone (n=13), or combination of anti-thymocyte globulin and cyclosporine (n=42). Combination therapy appeared to reach superior response rates in comparison to single agents (Table 1).

More recently, the monoclonal antibody against CD52 alemtuzumab was used as single agent in a pilot study of 21 selected patients with MDS (51). Patients were selected based on their likelihood to respond to anti-thymocyte globulin (young age, low IPSS score, and the presence of HLA DR15). The authors observed a significant response rate among patients with intermediate-1 MDS (15 out of 16 patients), but also among patients with intermediate-2 MDS (2 out of 5 patients). Interestingly, five of seven patients with abnormal karyotype had complete cytogenetic remission, including one patient with monosomy 7.

CONCLUSION

Evidence for an immune-mediated process in some cases of MDS, including hMDS, has been accumulated in the last decades. This knowledge has clinical implications in the selection of patients who might benefit from immunosuppressive regimens to alleviate cytopenias or even induce cytogenetic responses and novel less toxic agents may be very beneficial to selected patients. An immune-mediated mechanism is not restricted to hMDS, and the bone marrow cellularity in MDS may be the consequence of a delicate dynamic balance between the marrow microenvironment, proliferation capacity of the abnormal clone, intensity of the immune attack towards the marrow, and inhibition of normal hematopoiesis. Although hMDS is not classified as a defined category according to the WHO classification, MDS patients with a hypocellular marrow tend to have a less dramatic clinical course and a lower probability to evolve to leukemia.

Acknowledgments

This work was supported by the NIH Intramural Research Program.

Reference List

1. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of *RPS17* as a 5q⁻ syndrome gene by RNA interference screen. *Nature*. 2008; 451:335–337. [PubMed: 18202658]
2. List A, Kurtin S, Roe DJ, Buress A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. *N Engl J Med*. 2005; 352:549–557. [PubMed: 15703420]
3. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.. Lyon: International Agency for Research on Cancer; 2008.
4. Marisavljevic D, Cemerikic V, Rolovic Z, Boskovic D, Colovic M. Hypocellular myelodysplastic syndromes: clinical and biological significance. *Med Oncol*. 2005; 22(2):169–175. [PubMed: 15965280]
5. Lorand-Metze I, Pinheiro MP, Ribeiro E, De Paula EV, Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. *Leuk Res*. 2004; 28(6):587–594. [PubMed: 15120935]
6. Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. *Leuk Res*. 2008; 32(4):553–558. [PubMed: 17888511]
7. Sloand EM, Wu C, Greenberg P, Young NS, Barrett AJ. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. *J Clin Oncol*. 2007; 26:2505–2511. [PubMed: 18413642]

8. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. *Haematologica*. 2009; 94:264–268. [PubMed: 19144661]
9. Sloand EM, Barrett AJ. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. *Hematol Oncol Clin North Am*. 2010; 24(2):331–341. [PubMed: 20359629]
10. Otawa M, Kawanishi Y, Iwase O, Shoji N, Miyazawa K, Ohyashiki K. Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. *Leuk Res*. 2000; 24:359–366. [PubMed: 10713334]
11. Choi JW, Fujino M, Ito M. F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia. *Int J Hematol*. 2002; 75(3):257–260. [PubMed: 11999352]
12. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycosphosphatidyl inositol-anchored protein-deficient clones. *Brit J Haem*. 2001; 115:1015–1022.
13. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. *Blood*. 2002; 100:3897–3902. [PubMed: 12393738]
14. Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?". *J Clin Invest*. 2000; 106:637–641. [PubMed: 10974016]
15. Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, et al. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. *Haematologica*. 2009; 94(1):29–37. [PubMed: 19001281]
16. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. *Blood*. 2008; 111:4446–4455. [PubMed: 18239083]
17. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. *Blood*. 2009; 113:6549–6557. [PubMed: 19282459]
18. Calado RT, Regal JA, Kleiner DE, Schrupp DS, Peterson NR, Pons V, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. *PLoS one*. 2009; 4:e7926. [PubMed: 19936245]
19. Cooper JN, Calado R, Wu C, Scheinberg P, Young NS. Telomere Length of Peripheral Blood Leukocytes Predicts Relapse and Clonal Evolution after Immunosuppressive Therapy in Severe Aplastic Anemia. *Blood*. 2008; 442 Ref Type: Abstract.
20. Yamaguchi H, Baerlocher GM, Lansdorp PM, Chanock SJ, Nunez O, Sloand EM, et al. Mutations of the human telomerase RNA gene (*TERC*) in aplastic anemia and myelodysplastic syndrome. *Blood*. 2003; 102:916–918. [PubMed: 12676774]
21. Calado RT, Prince C, Peterson NR, Young NS, Maciejewski JP. Mutations in the Telomerase Reverse Transcriptase Gene Predisposes to Myelodysplastic Syndromes. *Blood*. 2009; 114:415. Ref Type: Abstract. [PubMed: 19429871]
22. Ortmann CA, Niemeyer CM, Wawer A, Ebell W, Baumann I, Kratz CP. *TERC* mutations in children with refractory cytopenia. *Haematologica*. 2006; 91:707–708. [PubMed: 16670076]
23. Engin H, Kuzu I, Ustundag Y, Aydemir S, Akoz AG, Kilincarslan D. Dyskeratosis congenita associated with hypocellular myelodysplastic syndrome: a case report. *Am J Med Sci*. 2007; 334(3):206–208. [PubMed: 17873535]
24. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. *Leuk Res*. 1996; 20:891–900. [PubMed: 9009245]
25. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, et al. Overexpression of tumor necrosis factor (TNF)- α and interferon (INF)- γ by bone marrow cells from patients with myelodysplastic syndromes. *Leukemia*. 1997; 11:2049–2054. [PubMed: 9447819]
26. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Over-expression of tumor necrosis factor- α in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. *Eur J Haematol*. 2005; 75(6):485–491. [PubMed: 16313260]

27. Verhoef GE, Schouwer P, Ceuppens JL, Van Damme JO, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndrome. *Leukemia*. 1992; 6:1268–1272. [PubMed: 1280751]
28. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. *Blood*. 2001; 98(10):3058–3065. [PubMed: 11698291]
29. Kitagawa M, Takahashi M, Yamaguchi S, Inoue M, Ogawa S, Hirokawa K, et al. Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. *Leukemia*. 1999; 13:699–703. [PubMed: 10374872]
30. Selleri C, Sato T, Raiola AM, Rotoli B, Young NS, Maciejewski JP. Induction of nitric oxide synthase is involved in the mechanism of fas-mediated apoptosis in haemopoietic cells. *Br J Haematol*. 1997; 99:481–489. [PubMed: 9401054]
31. Kornblau SM, McCue D, Singh N, Wenjing C, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. *Blood*. 2010 In press.
32. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of 16 putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. *Lancet*. 2004; 364:355–364. [PubMed: 15276395]
33. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. *Blood*. 2006; 108:2511–2521.
34. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. *Blood*. 2002; 100:3639–3645. [PubMed: 12393644]
35. Wlodarski MW, Gondek L, Nearman Z, O'Keefe C, Rodriguez A, Maciejewski JP. Molecular analysis of CTL responses in myelodysplastic syndrome and other bone marrow failure states. *Leukemia Research*. 2005; 29:S21. Ref Type: Abstract.
36. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED, et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. *Blood*. 2006; 108:2632–2641. [PubMed: 16614248]
37. Nishimura M, Yamada T, Andoh T, Tao T, Emoto M, Ohji T, et al. Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. *Int J Hematol*. 1998; 68:203–211. [PubMed: 9803678]
38. Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. *Blood*. 1994; 84:4257–4261. [PubMed: 7994040]
39. Sauntharajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. *Blood*. 2002; 100(5):1570–1574. [PubMed: 12176872]
40. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature*. 2010; 464(7290):852–857. [PubMed: 20305640]
41. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. *Nat Genet*. 2003; 33:97–101. [PubMed: 12496757]
42. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. *Br J Haematol*. 1998; 200:304–309. [PubMed: 9488617]
43. Yamada T, Tsurumi H, Kasahara S, Hara T, Sawada M, Moriwaki H. Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. *J Cancer Res Clin Oncol*. 2003; 129(8):485–491. [PubMed: 12856174]

44. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. *Brit J Haem.* 2003; 120:670-284.
45. Yazji S, Giles FJ, Tsimberidou A-M, Estey EH, Kantarjian HM, O'Brien SA, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. *Leukemia.* 2003; 17:2101-2106. [PubMed: 12931212]
46. Stadler M, Germing U, Kliche K-O, Josten KM, Hofmann W-K, Schrezenmeier H, et al. A prospective, randomised, phase II study of horse antithymocyte globulin *vs* rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. *Leukemia.* 2009; 18:460-465. [PubMed: 14712285]
47. Steensma DP, Dispenzieri A, Terreri A. Predicting response to ATG for patients with myelodysplastic syndrome. *Blood.* 2003; 102:3852. [PubMed: 14597611]
48. Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. *Haematologica.* 2006; 91(5):667-670. [PubMed: 16670072]
49. Atoyebi W, Bywater L, Rawlings L, Brunskill S, Littlewood TJ. Treatment of myelodysplasia with oral cyclosporin. *Clin Lab Haematol.* 2002; 24(4):211-214. [PubMed: 12181023]
50. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party. *Blood.* 1999; 93:2191-2195. [PubMed: 10090926]
51. Sloan EM, Olnes MJ, Weinstein B, Scheinberg P, Young NS. Alemtuzumab Treatment of Intermediate-1 (INT-1) Myelodysplasia Patients Is Associated with Sustained Improvement in Blood Counts and Cytogenetic Remissions. *Blood.* 2009; 114:116. Ref Type: Abstract.

Immunosuppressive therapies for MDS

Table 1

Center	N	Treatment	Median Age (years)	% RA	% Response
Prague (Jonasova 1998)	17	CsA	57	94	82
St. George's(44)	30	ATG	55	62	50
M.D. Anderson(45)	32	ATG + CsA	59	58	16
Germany(46)	35	ATG	63	68	34
Gifu, Japan(43)	18	MP + CsA	67	56	33
Karolinska(48)	20	ATG + CsA	62	85	30
NIH(7)	129		60	40	30
	74	ATG	-	-	24
	42	ATG + CsA	-	-	45
	13	CsA	-	-	8
NIH(51)	21	Alemtuzumab	-	-	81

RA, refractory anemia MDS; CsA, cyclosporine A; ATG, anti-thymocyte globulin.